Pharma People

Questionnaire for Study on Impact of FTA on Domestic Pharma Industry
A.
Economic
Q.1
In your view, do exports of drugs offer a major growth opportunity for Indian drug
manufacturing companies?
Q.2
Your plans for expansion of your presence in the global market for the next three
years?
Q.3
How do you foresee FTAs being beneficial or detrimental to the domestic pharma
industry? Please elaborate the basis of your views?
Q.4
Which specific pharma products are, in your view, presently facing unhealthy
competition?
Q.5
In your opinion, will FTAs provide a fillip to research & development in

pharmaceuticals in the country.
Q.6
Will FTAs in pharmaceuticals lead to attracting MNCs to shift their research

activities to India?
Q.7
What tax benefits can the Govt. of India provide to facilitate R&D in India?
Q.8
What would be the overall impact of FTAs on exports of pharmaceuticals products

covered under the Indian System of Medicine?
Q.9
Does the existing Govt. policy on Drug Pricing support the domestic pharma
industry? Please elaborate your view.
Q.10
Your suggestions for combating the menace of spurious drugs?
B.
Technical
Q.1
Please list the names of the drugs and formulations manufactured at your plant.
Q.2
Please furnish the annual production of each of the above mentioned drugs for the
years 2003-04, 2004-05 and 2005-06 as per Proforma-T1.
Q.3
Please furnish the standard and actual raw materials, chemicals and intermediates
consumption per kg of production, in respect of each of the drugs mentioned above,
for the years 2003-04, 2004-05 and 2005-06 as per Proforma-T2.
Q.4
Please comment whether any of the input raw materials, chemicals and
intermediates used in the manufacture of above drugs are imported. If yes, then
please mention the reasons (like non-availability of indigenous materials, quality,
price differential, etc.) for necessitating imports.
Proforma-T1
Annual Production of Drugs
(in quantitative terms)
S.No.
1.
Name of Drug
HS Code
Unit
Annual Production
2003-04 2004-05 2005-06
(pl.specify)
2.
3.
4.
.
.
.
.
.
.
.
.
.
.
Proforma-T2
Standard and Actual Raw Materials Consumption per kg of Production of the Drug
(separately for each of the drugs)
Name of Name of the HS

the Drug Raw
Code
materials/che
micals/interm
ediates
Whether
Unit
rawmaterials/ch
emicals are
imported or
indigenous
Standard
Consumptio
n per kg of
production
of the drug
Actual consumption
per
kg
of
production of the
drug
2003
-04
(1) ..
(pl.
specify)
(2) ..
(pl.
specify)
(3) ..
(4) ..
1 pl. specify
2
3
.
.
.
1 pl. specify
2
3
.
.
.
1 pl. specify
2
3
.
.
.
.
.
.
.
.
2004
-05
2005
-06
C. Costing
1.
Companys audited Balance Sheet and Profit & Loss for the year 2003-04, 2004-05 and
2005-06 may please be furnished.
2.
An elaborate statement regarding impact of Free Trade Agreements (FTA) entered into
by India with countries such as Sri Lanka, Thailand, Singapore etc. on the financial
performance of your company. The impact so assessed, whether positive or negative,
may be analysed with respect to respective countries in a product-specific manner.
3.
In what way the company has been benefited by way of those FTAs especially in
reduction in cost of production due to low cost of imported inputs, if any. This may be
supported with product-wise detailed facts and figures.
4.
Significant increase, if any, both in terms of quantity and value, in the export of
products, separately for bulk drug and formulations to the FTA countries after the date
of signing those agreements. The reasons attributed to such increased export may be
further elaborated.
5.
Whether the company perceive any threat to its operations in financial terms, in respect
of any of its products due to the FTAs already signed and those expected to be signed
with other countries.
6.
Any other submission on costing and financial aspects the company wishes to make in
favour of or against FTAs.
*************
No. 3/23/2005-TC
Government of India
Ministry of Commerce & Industry
Department of IP&P
Tariff Commission
7th Floor, Lok Nayak Bhawan,
Khan Market, New Delhi.
Dated:
Feb15, 2007
To,
Subject:- Study on impact of FTAs on Indian Pharma Industry.
*****
Sir,
The Department of Chemicals and Petrochemicals have entrusted Tariff Commission to
conduct a study on the Impact of Free Trade Agreements on Domestic Pharma Industry. In this
context, the Tariff Commission has devised a Questionnaire (copy enclosed). I may mention that
your name has been provided by Indian Drug Manufacturers Association for the purpose of
collection of data. You are requested to furnish the information by e-mail in the prescribed form to
the undersigned on [email protected] on priority basis and latest by March 12, 2007.
Thanking you,
Yours faithfully,
( Seema Gaur )
Adviser & Study Coordinator
1.
Mr. Sudhir Kaval,

Medisynth Chemicals Pvt. Ltd,.
[email protected]
2.
Mr. S.R. Banatwala,

Meridian Enterprises Pvt. Ltd.,
[email protected]
3.
Mr. B.H. Patel,

Morvel Labs (P) Ltd.,
[email protected]
4.
Mr. Moham Motawani,

Megha Labs Pvt. Ltd.,
[email protected]
5.
Mr. M.H. Mehta,

Mehtachem Industries,
[email protected]
6.
Dr. V. Chandrashekhar,
Kores (India) Ltd.,
[email protected]
7.
Mr. H.H. Pandit,

M.J. Biopharm Pvt. Ltd.,
[email protected]
8.
Dr. D. Patel,
Themis Laboratories Limited,
[email protected]
9.
Mr. U.M. Deshpande,

Milan Laboratories India,
[email protected]
10.
Mr. K.R. Patel,

Troikaa Pharmaceuticals Ltd.,
[email protected]
11.
Mr. R.G. Mehta,

ICPA Health Products Ltd.,
[email protected]
12.
Mr. R.C. Bora,

Twilight LI-Taka Pharma,
[email protected]
13.
Mr. A. Thacker,
Flamingo Pharmaceuticals Ltd.,
[email protected]
14.
Mr. N. Kashyap,
Indchemie Health Specialities Pvt. Ltd.,
[email protected]
15.
Mr. Abhay Kanoria,

Anglo French Drugs & Indls. Ltd.,
[email protected]
16.
Mr. C.D. Bendre,

Meyer Organics Pvt. Ltd.,
[email protected]
17.
Mr. D.S. Coulagi,

Sigma Laboratories Ltd.,
[email protected]
18.
Mr. B. Chudgar,
Intas Pharmaceuticals Ltd.,
[email protected]
19.
Mr. Shirish Dabir,

Emcure Pharmaceuticals Ltd.,
[email protected]
20.
Dr. R. Agarwal,
Macleods Pharmaceuticals Ltd.,
[email protected]
21.
Mr. Darshan Patel,

Paras Pharmaceuticals Ltd.,
[email protected]
22.
Mr. S.G. Kare,

Indoco Remedies Ltd.,
[email protected]
23.
Mr. Arvind Kumar B. Shah,

Arvind Remedies Ltd.,
[email protected]
24.
Mr. P.R. Sonawala,

Ajanta Pharma Ltd.,
[email protected]
25.
Mr. N.H. Israni,

Blue Cross Laboratories Ltd.,
[email protected]
26.
Mr. D.M. Parekh,

Zandu Pharmaceuticals Works Ltd.,
[email protected]
27.
Mr. Lalit Mittal,

Parental Drugs (India) Ltd.,
[email protected]
28.
Dr. Kiran Mazumdar Shaw,

Biocon Ltd.,
[email protected]
29.
Mr. K. Anji Reddy,

Dr. Reddys Laboratories Ltd.,
[email protected]
30.
Dr. I.S. Gandhi,

Aurobindo Pharma Ltd.,
[email protected]
31.
Mr. S. Kanan,
Lupin Ltd.,
[email protected]
32.
Mr. P.R. Patel,

Cadila Healthcare Ltd.,
[email protected]
33.
Mr. Dilip Shanghvi,

Sun Pharmaceutical Industries Ltd.,
[email protected]

Pharma People

Uploaded by

Copyright:

Available Formats

Pharma People

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Pharma People

Uploaded by

Copyright:

Available Formats

Questionnaire for Study on Impact of FTA on Domestic Pharma Industry

In your opinion, will FTAs provide a fillip to research & development in

Will FTAs in pharmaceuticals lead to attracting MNCs to shift their research

What would be the overall impact of FTAs on exports of pharmaceuticals products

Your suggestions for combating the menace of spurious drugs?

Name of Name of the HS

Mr. Sudhir Kaval,

Mr. S.R. Banatwala,

Mr. B.H. Patel,

Mr. Moham Motawani,

Mr. M.H. Mehta,

Mr. H.H. Pandit,

Mr. U.M. Deshpande,

Mr. K.R. Patel,

Mr. R.G. Mehta,

Mr. R.C. Bora,

Mr. Abhay Kanoria,

Mr. C.D. Bendre,

Mr. D.S. Coulagi,

Mr. Shirish Dabir,

Mr. Darshan Patel,

Mr. S.G. Kare,

Mr. Arvind Kumar B. Shah,

Mr. P.R. Sonawala,

Mr. N.H. Israni,

Mr. D.M. Parekh,

Mr. Lalit Mittal,

Dr. Kiran Mazumdar Shaw,

Mr. K. Anji Reddy,

Dr. I.S. Gandhi,

Mr. P.R. Patel,

Mr. Dilip Shanghvi,

You might also like